Lacosamide versus topiramate in episodic migraine: a randomized controlled double-blinded trial.

ABSTRACT:

Background

Although migraine is the second most prevalent form of headache, its preventive treatment has some contraindications and complications. It has been postulated that lacosamide reacts with collapsin response mediator protein 2 and prevents its phosphorylation, inhibiting calcitonin gene-related peptide release in the trigeminal system, which might have a role in migraine management.

Objective

Our study aimed mainly to evaluate the efficacy and safety of lacosamide as an alternative medication to topiramate for the prevention of migraine, especially in patients who had contraindications to topiramate and other approved antiseizure medications used for migraine prevention.

Design

Our study included two parallel groups: the lacosamide and the topiramate groups.<

SUBMITTER: Zeinhom MG 

PROVIDER: S-EPMC12690048 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature